In order to determine the functional consequences of these mutations, we expressed wild-type and mutant GALE proteins in 293T cells.. In this study we generated expression plasmids conta
Trang 1epimerase (GALE) associated with galactosemia in Korean patients using mammalian GALE-null cells
You-Lim Bang1,*, Trang T T Nguyen1,*, Tram T B Trinh1,*, Yun J Kim1, Junghan Song2 and Young-Han Song1
1 Ilsong Institute of Life Science, Hallym University, Anyang, Korea
2 Department of Laboratory Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea
Galactose is metabolized by three enzymes:
galactokin-ase, galactose 1-phosphate uridyltransferase and
UDP-galactose-4-epimerase (GALE; EC 5.1.3.2) [1] Defects
in any of these enzymes lead to the autosomal
reces-sive disorder, galactosemia [2] The majority of
patients with GALE-deficiency galactosemia
(MIM 230350) are identified as having a clinically
benign ‘peripheral’ condition These patients show
defective GALE activity only in circulating red and
white blood cells, and the condition is relatively
com-mon in African Americans [3] and in Japanese [4] The
clinically severe ‘generalized’ form of GALE-deficiency,
galactosemia, is extremely rare and enzyme activity is
defective in all tissues examined These patients show growth retardation and developmental delay [5] ‘Inter-mediate GALE deficiency’ has also been applied to patients who exhibit partial impairment of GALE activity in nonperipheral cells, such as lymphoblasts [6] The molecular mechanisms that distinguish these subtypes of GALE-deficiency galactosemia have not been identified
GALE is a member of the short-chain dehydroge-nase⁄ reductase superfamily It is widely distributed in nature and has been isolated and characterized in several species [7–9] The 3D structure of Escherichia coli [10], Trypanosoma brucei [11], Saccharomyces
Keywords
galactosemia; mutation; protein aggregation;
UDP-galactose-4-epimerase; unstable
protein
Correspondence
Y.-H Song, Ilsong Institute of Life Science,
Hallym University, 1605-4 Gwanyang-dong,
Dongan-gu, Anyang, Gyeonggi-do 431 060,
Korea
Fax: +82 31 388 3427
Tel: +82 31 380 1897
E-mail: ysong@hallym.ac.kr
*These authors contributed equally to this
work
(Received 15 December 2008, revised 19
January 2009, accepted 21 January 2009)
doi:10.1111/j.1742-4658.2009.06922.x
Galactosemia is caused by defects in the galactose metabolic pathway, which consists of three enzymes, including UDP-galactose-4-epimerase (GALE) We previously reported nine mutations in Korean patients with epimerase-deficiency galactosemia In order to determine the functional consequences of these mutations, we expressed wild-type and mutant GALE proteins in 293T cells GALEE165K and GALEW336X proteins were unstable, had reduced half-life, formed aggregates and were partly degraded by the proteasome complex When expressed in GALE-null ldlD cells GALEE165K, GALER239W, GALEG302D and GALEW336X had no detectable enzyme activity, although substantial amounts of protein were detected in western blots The relative activities of other mutants were lower than that of wild-type In addition, unlike wild-type, GALER239W and GALEG302D were not able to rescue galactose-sensitive cell prolifera-tion when stably expressed in ldlD cells The four inactive mutant proteins did not show defects in dimerization or affect the activity of other mutant alleles identified in patients Our observations show that altered protein stability is due to misfolding and that loss or reduction of enzyme activity
is responsible for the molecular defects underlying GALE-deficiency galactosemia
Abbreviations
BrdU, bromodeoxyuridine; CHO, Chinese hamster ovary; EGFP, enhanced green fluorescent protein; GALE, UDP-galactose 4¢-epimerase; UDP-galNAc, UDP-N-acetylgalactosamine; UDP-glcNAc, UDP-N-acetylglucosamine.
Trang 2cerevisiae [12] and human [13] GALE has been
determined by high-resolution X-ray crystallography
GALE from all species examined to date, with the
exception of the bacterium, Aeromonas hydrophila
functions as a dimer [14] Since the cloning of
human GALE in 1995 [15], 22 mutations have been
identified in the GALE coding sequences of
GALE-deficiency galactosemia patients (Fig S1A) [5,6,16–
21] To understand the functional consequences of
the mutations, biochemical studies have been carried
out by expressing wild-type and mutant human
GALE in bacteria or in yeast null for the GALE
homologue, gal10p Among the 12 mutants
charac-terized to date, the most severe defects in GALE
protein were observed with mutants G90E, V94M
and L183P Mutants G90E and V94M show a
reduc-tion in turnover number by factors of 800 and 30,
respectively [22], and are unable to restore
galactose-sensitive growth when expressed in epimerase-null
yeast [18] Even though the turnover number of
mutant L183P is lower than that of wild-type GALE
by a factor of three [22], the relative abundance of
this mutant protein was greatly reduced in bacteria
[22] and yeast [23], thereby decreasing the relative
enzymatic activity to 4% of wild-type protein [23]
Mutants N34S, P293L and G319E show the mildest
defects in turnover number (reduced by factors of
1.1, 1.8 and 1.2, respectively) [22] The remainder of
the mutant alleles characterized to date do not show
substantial defects in the restoration of
galactose-sensitive growth in yeast [21,24] and show a mild
reduction in turnover number (decrease by a factor
of 2.4–7.2) [22] None of the mutant human GALE
tested to date show defects in dimerization [21,22]
and mutant alleles N34S and L183P are dominant
negative with respect to each other [23] These results
suggest that not all mutant alleles found in
patients cause functional defects and underscore the
importance of functional studies on the mutant
proteins
We previously described nine GALE mutations in
Korean patients with GALE-deficient galactosemia
[20] These GALE mutations were novel with the
exception of R335H, which had been shown earlier to
cause mild defects in enzyme activity [19,22] In this
study we generated expression plasmids containing
wild-type and mutant GALE cDNA from Korean
galactosemia patients and expressed the constructs in
293T or GALE null ldlD cells [25] to examine the
functional consequences of the mutations Our study
showed that GALEE165K, GALER239W, GALEG302D
and GALEW336Xexhibited no detectable enzyme
activ-ity, and GALEE165K and GALEW336X formed protein
aggregates and showed greatly reduced stability More-over, unlike wild-type proteins, the two stable inactive mutants, GALER239W and GALEG302D, were unable
to rescue defects in galactose-sensitive cell prolifera-tion, confirming that these mutants are not functional
in vivoeither
Results
Protein stability
To investigate the functional properties of the mutant GALE proteins, full-length wild-type or mutant GALE cDNAs were cloned into expression plasmids containing N-terminal myc or FLAG epitopes When transiently expressed in 293T cells, steady-state levels of myc– GALEE165Kand myc–GALEW336Xproteins were signifi-cantly reduced compared with wild-type, even though the transfection efficiencies, based on the expression level of cotransfected enhanced green fluorescent protein (EGFP), were comparable (Fig 1A) The steady-state levels of FLAG-tagged GALEE165K and GALEW336X were similarly reduced (data not shown)
The steady-state protein level can be decreased by mutations because of reductions in either RNA or pro-tein stability In order to distinguish between the two possibilities, we performed semi-quantitative RT-PCR using GALE transgene-specific primers and EGFP as both an internal control and control for transfection efficiency The amount of PCR product increased upon addition of threefold more cDNA template, confirming that a plateau was not reached under these PCR con-ditions The levels of GALEE165K and GALEW336X transcripts were not significantly different from that of wild-type, suggesting that these mutations did not alter RNA stability (Fig 1B)
We tested the stability of the mutant proteins by determining protein half-life using cycloheximide Wild-type GALE produced stable protein with a half-life of > 8 h Unlike that of wild-type, the half-half-life of GALEE165Kand GALEW336Xproteins decreased to 2.0 and 2.1 h, respectively (Fig 1C) In order to determine whether the mutant proteins are degraded by the proteasome complex, we investigated the effect of the proteasome inhibitor, MG132 on protein half-life
In the presence of MG132, the half-lives of GALEE165K and GALEW336X were increased signi-ficantly up to 8.7 and 6.7 h, respectively, but MG132 treatment does not appear to restore the steady-state protein level to that of wild-type (Fig 1D) These results suggest that GALEE165K and GALEW336X are unstable proteins which are degraded to some extent by the proteasome complex
Trang 3Subcellular localization
We performed indirect immunofluorescence to
deter-mine whether the subcellular localization of GALE is
altered by the mutations Wild-type GALE showed a
pattern of diffuse cytoplasmic immunoreactivity when expressed in 293T cells (Fig 2A) Mutant proteins showed a distribution pattern similar to wild-type (data not shown), with the exception of GALEE165K
A
B
C
D
Fig 1 GALE E165K and GALE W336X proteins have shorter half-lives and are degraded by proteasome complex (A, B) Empty vector ( )), wild-type (WT) or mutant myc–GALE expression plasmids were co-transfected into 293T cells with EGFP expression construct as a control for transfection efficiency Forty hours after transfection, cell lysates or total RNA were prepared and western analysis (A) or RT-PCR (B), respectively, were carried out (A) Myc–GALE and EGFP were detected using antibodies against myc and GFP by western analysis (B) Equal amount of total RNA prepared from transfected cells was reverse transcribed and 1 or 3 lL of cDNA was used to amplify EGFP and myc–GALE (C) In order to determine the half-life of myc–GALE wt , myc–GALE E165K and myc–GALE W336X proteins, 293T cells transiently transfected with each myc–GALE expression plasmid were equally divided among the wells of a six-well plate and treated with 50 lgÆmL)1 cycloheximide (CHX) At the indicated time intervals, the cells were harvested and analyzed by western blotting The amount of extract from cells expressing mutant GALE was increased to reach a detectable level of protein Tubulin serves as a loading control The relative amount
of mutant protein was calculated based on the ratio of the band intensities of myc-GALE to tubulin in the western blot and indicated below the blot with 100 set as the zero time point The relative levels of myc–GALE protein at each time point were plotted using a complete linear least squares curve-fit algorithm, and the time point at which GALE levels decreased to 50% of their original value was determined and reported as the half-life (D) In parallel experiments, cells were treated with 25 l M of the proteosome inhibitor, MG132, 1 h prior to and for the duration of cycloheximide treatment.
Trang 4aggregates The appearance of the aggregates varied
and presented as a single, large perinuclear sphere,
sev-eral smaller spheres or perinuclear aggregates with
additional, multiple foci throughout the cytoplasm
(Fig 2A) In some cells, the mutant proteins were also
observed in the cytoplasm, as seen for the wild-type
protein Similar staining patterns were observed in
other human cell lines, including hepatoma Hep3B
cells and fibroblast 2fTGH cells (data not shown),
sug-gesting that mislocalization of the mutant proteins was
not cell-type-specific Aggresomes are structures
formed in the presence of misfolded proteins and
con-tain components of the protein degradation and
refold-ing machinery, includrefold-ing proteasome complexes and
members of the Hsc70 and Hsp70 families of proteins
[26,27] Because the morphological appearance of
aggresomes is similar to the aggregates seen in cells expressing mutant GALE, we investigated whether Hsc70 is recruited to the GALEE165Kand GALEW336X aggregates Unlike cells expressing wild-type GALE, cells transfected with GALEE165K and GALEW336X showed Hsc70 redistribution and Hsc70 colocalized with the GALE proteins, suggesting that these mutant proteins indeed become incorporated into aggresomes
GALE activity towards UDP-galactose
To determine the functional consequences of the muta-tions, we expressed wild-type and mutant GALE in the GALE-null cell line, ldlD, derived from Chinese hamster ovary (CHO) cells [25,28] As shown previ-ously, ldlD cells did not exhibit any GALE activity (data not shown), whereas cells expressing myc- or FLAG-tagged wild-type GALE were able to catalyze the conversion of UDP-galactose into UDP-glucose Enzyme activities of myc-tagged GALEE165K, GALER239W, GALEG302Dand GALEW336Xwere unde-tectable even though substantial amounts of the proteins were detected (Fig 3) Results were the same for FLAG-tagged constructs (data not shown) It is interesting to note that the steady-state levels of GALEE165K and GALEW336X proteins in ldlD cell
E165K E165K
E165K
GALE
B
A
wt
E165K
W336X
Fig 2 GALE E165K and GALE W336X proteins form aggresomes in
the cell (A) Wild-type and mutant myc–GALE proteins were
expressed in 293T cell and immunohistochemistry was carried out
to visualize GALE proteins using mouse anti-myc mAb and
rhoda-mine-conjugated anti-mouse IgG (red) Nuclei are stained with DAPI
(blue) (B) 293T cells were transfected with FLAG–GALE and
stained for FLAG–GALE (red) and Hsc70 (green).
n = 3
80 100 120
40 60
0 20
A25V R40C D69E
∗
∗
E165K R239W G302D W336X R169W R335H
myc-GALE Tubulin
Fig 3 Relative enzymatic activities of wild-type and mutant GALE proteins expressed in ldlD cells Cell lysates prepared from ldlD cells transiently transfected with wild-type and mutant myc–GALE were analyzed for enzyme activity using UDP-galactose as sub-strate Enzyme activity was normalized against the relative protein abundance calculated from the intensities of myc–GALE and tubulin bands in the western blot A representative blot is shown Values represent the mean and standard deviation of relative enzyme activities, with wild-type activity set as 100% At least three trans-fections were carried out for each point Asterisks signify no detectable enzyme activity.
Trang 5lysates appear similar to that of wild-type, unlike what
we observed in 293T cells (compare Figs 1A and 3)
This is likely to be caused by differences in the time of
harvest and the methods used to extract proteins (see
Materials and methods for detail), because mutant
protein levels were dramatically decreased when ldlD
cell lysates were prepared similar to 293T cells (data
not shown) The relative enzyme activities of the other
mutants were also affected and decreased to 24–71%
of the wild-type level (Fig 3) Thus, the enzyme
activi-ties of the E165K, R239W, G302D and W336X
mutant proteins were not detectable, whereas the
remainder of the mutants showed only mild defects
Restoration of galactose-sensitive proliferation
defects of ldlD cells
GALE-null ldlD cells show defects in cell proliferation
when grown in the presence of galactose [28] This
sen-sitivity to galactose can be rescued by expressing
wild-type GALE and the degree of rescue is dependent on
the level of GALE enzyme activity In order to test
whether the four inactive mutants can restore galactose
sensitivity, we generated stable cell lines expressing
myc-tagged wild-type and mutant proteins Although a
similar number of colonies was analyzed for each
mutant, we were not able to generate ldlD cell lines
that stably expressed GALEE165K or GALEW336X All
stable cell lines used in this assay showed proliferation
rates in the absence of galactose similar to that of ldlD
cells A bromodeoxyuridine (BrdU) incorporation
assay was performed in the presence and absence of
0.25 mm galactose The level of BrdU incorporated
into each cell line treated with galactose was
normal-ized relative to BrdU incorporation in the absence of
galactose, which was set to 100% (Fig 4) Similar to
the previous report, wild-type CHO and ldlD cells
incorporated 119% and 21% of the level of BrdU in
the presence of 0.25 mm galactose In the ldlD(myc–
GALE) wild-type lines, BrdU incorporation was
restored to 116% (wt #3), 88% (wt #11) and 52%
(wt #8); and the level restored was dependent on the
relative enzyme activity (29.0, 5.2 and 0.9, respectively)
and protein level (17.9, 1.0 and 0.2, respectively)
Because the relative enzyme activity of wt #11 was
5.2-fold higher than that of CHO cells and the level of
BrdU incorporation was restored to 88%, we selected
two independent stable lines for GALER239W and
GALEG302D, which expressed a similar or higher
(0.8-to 2.0-fold) level of mutant GALE expression
com-pared with wt #11 There was no detectable enzyme
activity in extracts of cells stably expressing either of
the two mutants and BrdU incorporation upon
galac-tose treatment decreased to 21–33% of control values, confirming that the GALER239W and GALEG302D proteins are non-functional in vivo as well
Dimerization and the dominant-negative effect
In order to test whether the loss of enzyme activity of the four mutants is due to defects in dimer formation,
we performed an immunoprecipitation assay We transfected FLAG- and myc-tagged wild-type GALE alone or together into ldlD cells and
immunoprecipitat-ed the protein with myc antibody When increasing amounts of lysate from cells transfected only with FLAG–GALE were immunoprecipitated, no GALE bands were detected on western blots probed with anti-body against FLAG or myc (Fig 5A) By contrast, FLAG–GALE was detected in the anti-myc immuno-precipitates of cell lysates expressing both myc–GALE and FLAG–GALE in a dose-dependent manner (Fig 5A), confirming that dimerization of the GALE proteins had taken place Similarly, GALEE165K, GALER239W, GALEG302D and GALEW336X were able
80.0 100.0 120.0 140.0
0.0 20.0 40.0 60.0
CHO ldlD wt
#3
wt
#1 1
wt
#8 R239W
#15 R239W
#5 G302D
#10 G302D
#13
Tubulin
myc-GALE
1.0 0.2 1.7 2.0 0.8 17.9 1.6
RP A REA (CHO:1) 29.0 5.2 0.9 0 0 0 0
Fig 4 GALE R239W and GALE G302D are not able to restore galac-tose-sensitive cell proliferation when stably expressed in ldlD cells.
Stable ldlD cells expressing varying amounts of myc–GALEwt, myc–GALE R239W and myc–GALE G302D were generated Relative proliferation of these cells in the presence and absence of 0.25 m M galactose was determined by measuring BrdU incorporation The level of BrdU incorporation into each cell line cultured in the absence of galactose was set to 100% and the corresponding results from galactose treated cells were calculated accordingly.
Relative protein abundance (RPA) was calculated based on the ratio
of intensity of the myc–GALE to tubulin bands in the western blot and normalized by setting the amount of GALE in ldlD(myc–GALE)
wt #11 as 1.0 The western blot for determining the protein level in extracts derived from each cell line is shown The relative enzyme activity (REA) was determined and normalized by setting the enzyme activity of CHO cell lysates as 1.0.
Trang 6to form homodimers (Fig 5B), suggesting that these
mutant proteins exist as dimers, even though their
enzymatic activity is severely compromised The four
mutant proteins were able to form heterodimers with
the alleles found in the patient (Fig 5C) Because
GALEN34S and GALEL183P are dominant-negative
with respect to each other [23], we investigated whether
the four inactive mutants have a similar effect When
tested in ldlD cells, we could not observe such effect
(Fig S2)
Discussion
Previously, we identified nine mutations in Korean
patients with GALE-deficiency galactosemia [20] Our
results on the functional consequences of these
muta-tions reveal that they could be categorized into three
groups The first group includes E165K and W336X,
which had no detectable GALE activity, formed
protein aggregates and were degraded by proteasome
complex The second group, consisting of R239W and
G302D, also exhibited no detectable enzymatic
activ-ity, although the stability of the proteins was
unaf-fected The remaining mutants showed mild defects in
enzyme activity with apparently wild-type protein
stability In this study, we utilized GALE null ldlD
cells to test enzyme activity and in vivo function of
GALE mutants The ability to rescue defects in cell
proliferation of galactose-treated ldlD cells correlated with the defects in enzyme activity Interestingly, stable cells expressing mutants showing mild defects in enzyme activity behaved in a manner similar to the original CHO cells (data not shown), suggesting that the mild defects did not affect this phenotype This is consistent with previous results in yeast showing a steep threshold relationship between growth rate in galactose and GALE activity [29]
W336X is the only nonsense mutation that has been identified in GALE-deficiency galactosemia patients It
is well known that mRNAs harboring premature ter-mination codons are rapidly degraded by the RNA surveillance mechanism known as nonsense-mediated mRNA decay [30] In mammalian cells, premature stop codons generally need to be at least 55 nucleotides upstream of the last intron in order to trigger mRNA decay [30] Because the W336X mutation generates a premature stop codon in the last exon, it is not likely
to induce nonsense-mediated mRNA decay In addi-tion, we could not detect changes in the mRNA stabil-ity caused by this mutation when the mutant protein was expressed from cDNA (Fig 1B)
When newly synthesized proteins are misfolded for a number of reasons, including missense mutation or lack
of oligomeric assembly partners, they aggregate to form
an aggresomal particle and are targeted for degradation
by the ubiquitin–proteasome system [26] The overall
A
B
C
Fig 5 Capacity of type and four mutant GALE proteins with undetectable enzyme activity to dimerize (A) FLAG- and myc-tagged wild-type GALE expression plasmids were transfected individually or in combination into ldlD cells and immunoprecipitation was carried out with myc antibody using detergent-soluble cell lysates containing the amount of protein indicated Immunoprecipitates (IP) were analyzed by wes-tern blotting (IB) with FLAG antibody, stripped, and reprobed with myc antibody (B) In order to determine if the four mutant proteins are able to form homo-dimers, FLAG- and myc-tagged GALE constructs were co-transfected and analyzed as in (A) (C) FLAG–GALE was trans-fected into stable ldlD lines expressing myc-GALE as indicated and immunoprecipitation was performed and analyzed as in (A).
Trang 7structure of aggresomes appears to vary depending on
the nature of the aggregating protein and the cell type: a
single sphere of diameter 1–3 lm or an extended
ribbon-shaped structure [26] It has been shown that the
machinery for protein refolding and degradation,
including such components as Hsc70, Hsp70, Hsp40
family of proteins and proteasomes are recruited to the
aggresome to eliminate the aggregated material [31]
Aggregated proteins that can not be refolded by the
chaperone system or degraded by the proteasomes are
efficiently removed by autophagy [26] The subcellular
distribution, co-localization with Hsc70 and
proteo-some-dependent degradation of GALEE165K and
GALEW336X proteins support the theory that these
mutant proteins are misfolded, form aggresomes and
are degraded by the proteasome complex Substitution
of the negatively charged amino acid, glutamate, with
the positively charged lysine (E165K) and deletion of
the 13 C-terminal amino acids (W336X) probably
dis-rupted normal protein folding Because previous reports
indicate that some protein aggregates have a toxic ‘gain
of function’ activity, it will be interesting to explore
whether aggregation of these GALE mutant proteins
results in pathological symptoms that are related to
tox-icity and independent of the symptoms caused by the
absence of GALE activity Consistent with this
possibil-ity, we were not able to generate stable cell lines
express-ing E165K and W336X mutant proteins, even though
the possibility of very low steady-state levels of protein
cannot be ruled out Further studies are required to
pursue this question
Unlike enzymes isolated from E coli and yeast,
mammalian GALE enzymes can convert
UDP-N-acet-ylgalactosamine (UDP-galNAc) to
UDP-N-acetylglu-cosamine (UDP-glcNAc), and are known to require
exogenous NAD+ [9] We did not test the GALE
mutations for enzyme activity on UDP-galNAc
Previ-ous reports show that GALEG90E and GALEV94M are
defective on both substrates [18] suggesting the
possi-bility that the above four mutants might have impaired
activity on UDP-galNAc It has been reported that
purified GALEN34S requires more than a fourfold
higher concentration of NAD+ to achieve
half-maxi-mal activity compared with the wild-type enzyme [23]
This result explains the observation that GALEN34S
present in crude yeast extracts demonstrated only 70%
of wild-type activity when assayed at 4 mm NAD+,
whereas less-pronounced differences were observed
when a higher concentration of NAD+was used [23]
We used 5 mm NAD+ in the enzyme activity assay
and it remains to be determined if any of the
muta-tions found in Korean galactosemia patients also show
increased dependence on exogenous NAD+
The results from this and previous reports identified seven amino acid residues with severe defects in enzyme activity and⁄ or protein stability (Fig S1A) When GALE sequences from eight species were aligned, approximately one third of the amino acids were strictly conserved in all species (Fig S1B) Of 20 amino acids that have been characterized, none of the mutations with mild defects are associated with these conserved amino acid residues, with the exception of N34S By contrast, all seven GALE mutants showing severe defects were identical in amino acid sequence among species (Fig S1B), underscoring the importance
of these amino acids in proper folding and catalytic activity of the protein The importance of Arg239 and Gly302 is further supported by existing evidence based
on X-ray crystallography data that these amino acids occur in a region which undergoes major conforma-tional change upon substrate binding [13] Moreover, Arg239 is one of the key amino acid residues that forms electrostatic interactions with the phosphoryl oxygens of the UDP-glucose [13]
In this report, we studied the functional conse-quences of nine mutations in Korean patients with epimerase-deficiency galactosemia We found that mutants E165K and W336X produced proteins with greatly reduced protein stability, probably due to misfolding, and they formed aggregates that were degraded by proteasomes In addition, these proteins also lacked enzyme activity By contrast, mutants R239W and G302D generated proteins with normal protein stability but lacking detectable enzyme activity These proteins also failed to rescue galactose-sensitive cell proliferation of ldlD cells We utilized ldlD cells and provided evidence that these cells will serve as an important system for future studies on the function of GALE Further studies are warranted to test whether previously identified unstable GALE alleles could form protein aggregates and if these aggregations are toxic
Materials and methods
Plasmids and cell culture Wild-type human GALE cDNA was kindly provided by
J L Fridovich-Keil (Emory University, Atlanta, GA, USA) Mutant GALE cDNAs were generated using the QuickChange Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA, USA) and were cloned into pCDNA3 (Invi-trogen, Carlsbad, CA, USA) or pCMV-Tag2A (Stratagene)
to produce GALE containing N-terminal myc or FLAG epitope, respectively All expression constructs were con-firmed by sequencing the entire coding region 293T, CHO-K1 cells (gift of M Krieger, Massachusetts Institute of
Trang 8Technology, Cambridge, MA, USA) and the ldlD cell line
(ATCC, Manassas, VA, USA) were maintained as
previ-ously described [28]
RT-PCR
293T cells grown in 60 mm dishes were transfected with
4 lg myc–GALE expression construct together with 0.3 lg
EGFP expression plasmid, pEGFP-C1 (Clontech, Palo
Alto, CA, USA) using the calcium phosphate method
Forty hours after transfection, total RNA was isolated and
equal amount of RNA (4 lg) was reverse transcribed using
SuperScript II reverse transcriptase (Invitrogen) and
0.5 mm oligo(dT)12–18as primer One or three microliters of
cDNA products were amplified with Taq DNA polymerase
in the presence of primers specific for the GALE transgene
and EGFP
Stability of GALE proteins
Forty hours after transfection 293T cells were harvested in
lysis buffer [50 mm Tris, pH 7.4, 0.5% Nonidet P-40,
150 mm NaCl, 1 mm EDTA and Complete Protease
Inhibi-tor Cocktail Tablet (Roche Applied Science, Mannheim,
Germany)] After centrifugation, the supernatant was
resolved by SDS⁄ PAGE and myc–GALE and EGFP
pro-teins were detected by western analysis using antibody
against myc (9E10; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and antibody against GFP (Santa Cruz) To
determine protein half-life, 293T cells grown in 100 mm
dishes were transfected with 10 lg wild-type or mutant
myc–GALE expression plasmid On the following day, cells
were evenly divided among the wells of a six-well plate and
allowed to incubate overnight Wells were treated with
50 lgÆmL)1cycloheximide (Sigma, St Louis, MO, USA) for
the durations indicated in the text In parallel experiments,
cells were treated with the 25 lm proteasome inhibitor,
MG132 (Calbiochem, San Diego, CA, USA) 1 h prior to
and for the duration of cycloheximide treatment The myc–
GALE protein levels were determined by western analysis
and tubulin levels were determined as a loading control
Immunofluorescence microscopy
293T cells grown on coverslips were transfected with myc–
GALE or FLAG–GALE, fixed with 4% paraformaldehyde
in NaCl⁄ Pifor 20 min, and permeabilized with 1% Nonidet
P-40⁄ 10 mm glycine for 5 min Cells on coverslips were
blocked in 3% BSA for 30 min Myc–GALE-transfected
cells were treated with anti-myc mAb followed by
rhoda-mine-conjugated goat anti-mouse IgG (Jackson
Immuno-Research Laboratories Inc, West Grove, PA, USA) GALE
and Hsc70 were detected in FLAG–GALE-transfected cells
using rabbit FLAG antibody and mouse Hsc70 antibody
followed by rhodamine-conjugated goat anti-rabbit IgG
and FITC-conjugated goat anti-mouse IgG Nuclei were stained with 10 lgÆmL)1 DAPI and observed by confocal fluorescence microscopy using a Zeiss 510 laser-scanning microscopy (Carl Zeiss, Jena, Germany)
GALE enzyme assay ldlD cells grown in 100 mm dishes were transfected with
5 lg GALE expression plasmid using 15 lL Lipofecta-min 2000 (Invitrogen) according to the manufacturer’s instructions and harvested 24 h later Cell pellets resus-pended in distilled water were sonicated and centrifuged The supernatant was used for the enzyme assay and wes-tern analysis to determine relative protein abundance GALE enzyme activity was determined using UDP-galac-tose as previously described [20,32] The relative protein abundance in each lysate was calculated by measuring the intensity of the individual GALE and tubulin bands in the western blot using Scion Image (Scion Corporation, Frederick, MD, USA)
Generation of stable cell lines and BrdU incorporation assays
In order to test the galactose sensitive proliferation of the cells, stable ldlD cell lines were generated and BrdU incor-poration assays were performed as described previously [28]
Dimerization
To determine whether the mutant GALE proteins are able to form homo- and heterodimers, we transfected sta-ble cell lines expressing wild-type or mutant myc–GALE allele with the FLAG–GALE expression constructs In the case of mutant myc–GALE, in which the expression level was low in the stable lines, we co-transfected both myc- and FLAG-tagged hGALE into ldlD cells Twenty-four hours after transfection, ldlD cells were harvested with lysis buffer (50 mm Tris, pH 7.4, 0.5% Nonidet P-40,
150 mm NaCl, 1 mm EDTA and Complete Protease Inhibitor Cocktail Tablet) and centrifuged The superna-tant was used for immunoprecipitation with myc antibody and precipitated protein was analyzed by western blotting Membranes were probed with anti-FLAG mAb, stripped, and re-probed with horseradish peroxidase-conjugated myc antibody Alternatively, the membranes were probed with rabbit FLAG antibody, stripped, and re-probed with anti-myc mAb
Acknowledgements
We wish to thank J L Fridovich-Keil of Emory University for providing the hGALE cDNA
Trang 9con-structs This study was supported by a grant from the
Seoul National University Research Fund (JS)
References
1 Holden HM, Rayment I & Thoden JB (2003) Structure
and function of enzymes of the Leloir pathway for
galactose metabolism J Biol Chem 278, 43885–43888
2 Fridovich-Keil JL (2006) Galactosemia: the good, the
bad, and the unknown J Cell Physiol 209, 701–705
3 Ng WG, Xu Y-K, Cowan TM, Blitzer MG, Allen RJ,
Bock H-GO, Kruckeberg WC & Levy HL (1993)
Eryth-rocyte uridine diphosphate galactose-4-epimerase
defi-ciency identified by newborn screening for galactosemia
in the United States Screening 2, 179–186
4 Misumi H, Wada H, Kawakami M, Ninomiya H,
Suei-shi T, Ichiba Y & Shohmori T (1981) Detection of
UDP-galactose-4-epimerase deficiency in a galactosemia
screening program Clin Chim Acta 116, 101–105
5 Walter JH, Roberts RE, Besley GT, Wraith JE, Cleary
MA, Holton JB & MacFaul R (1999) Generalised
uri-dine diphosphate galactose-4-epimerase deficiency Arch
Dis Child 80, 374–376
6 Openo KK, Schulz JM, Vargas CA, Orton CS, Epstein
MP, Schnur RE, Scaglia F, Berry GT, Gottesman GS,
Ficicioglu C et al (2006) Epimerase-deficiency
galacto-semia is not a binary condition Am J Hum Genet 78,
89–102
7 Darrow RA & Rodstrom R (1968) Purification and
properties of uridine diphosphate galactose 4-epimerase
from yeast Biochemistry 7, 1645–1654
8 Wilson DB & Hogness DS (1969) The enzymes of the
galactose operon in Escherichia coli II The subunits of
uridine diphosphogalactose 4-epimerase J Biol Chem
244, 2132–2136
9 Tsai CM, Holmberg N & Ebner KE (1970) Purification,
stabilization, and properties of bovine mammary
UDP-galactose 4-epimerase Arch Biochem Biophys 136,
233–244
10 Thoden JB, Frey PA & Holden HM (1996) Crystal
structures of the oxidized and reduced forms of
UDP-galactose 4-epimerase isolated from Escherichia coli
Biochemistry 35, 2557–2566
11 Alphey MS, Burton A, Urbaniak MD, Boons GJ,
Ferguson MA & Hunter WN (2006) Trypanosoma
bruceiUDP-galactose-4¢-epimerase in ternary complex
with NAD+ and the substrate analogue
UDP-4-deoxy-4-fluoro-alpha-d-galactose Acta Crystallogr Sect F
Struct Biol Cryst Commun 62, 829–834
12 Thoden JB & Holden HM (2005) The molecular
archi-tecture of galactose mutarotase⁄ UDP-galactose
4-epim-erase from Saccharomyces cerevisiae J Biol Chem 280,
21900–21907
13 Thoden JB, Wohlers TM, Fridovich-Keil JL & Holden
HM (2000) Crystallographic evidence for Tyr 157
func-tioning as the active site base in human UDP-galactose 4-epimerase Biochemistry 39, 5691–5701
14 Agarwal S, Gopal K, Upadhyaya T & Dixit A (2007) Biochemical and functional characterization of UDP-galactose 4-epimerase from Aeromonas hydrophila Biochim Biophys Acta 1774, 828–837
15 Daude N, Gallaher TK, Zeschnigk M, Starzinski-Po-witz A, Petry KG, Haworth IS & Reichardt JK (1995) Molecular cloning, characterization, and mapping of a full-length cDNA encoding human UDP-galactose 4¢-epimerase Biochem Mol Med 56, 1–7
16 Maceratesi P, Daude N, Dallapiccola B, Novelli G, Allen R, Okano Y & Reichardt J (1998) Human UDP-galactose 4¢ epimerase (GALE) gene and identification
of five missense mutations in patients with epimerase-deficiency galactosemia Mol Genet Metab 63, 26–30
17 Alano A, Almashanu S, Chinsky JM, Costeas P, Blitzer
MG, Wulfsberg EA & Cowan TM (1998) Molecular characterization of a unique patient with epimerase-defi-ciency galactosaemia J Inherit Metab Dis 21, 341–350
18 Wohlers TM, Christacos NC, Harreman MT & Frido-vich-Keil JL (1999) Identification and characterization
of a mutation, in the human UDP-galactose-4-epimer-ase gene, associated with generalized epimerUDP-galactose-4-epimer-ase-defi- epimerase-defi-ciency galactosemia Am J Hum Genet 64, 462–470
19 Henderson JM, Huguenin SM, Cowan TM & Frido-vich-Keil JL (2001) A PCR-based method for detecting known mutations in the human UDP galactose-4¢-epim-erase gene associated with epimgalactose-4¢-epim-erase-deficiency galacto-semia Clin Genet 60, 350–355
20 Park HD, Park KU, Kim JQ, Shin CH, Yang SW, Lee
DH, Song YH & Song J (2005) The molecular basis of UDP-galactose-4-epimerase (GALE) deficiency galacto-semia in Korean patients Genet Med 7, 646–649
21 Chhay JS, Vargas CA, McCorvie TJ, Fridovich-Keil JL
& Timson DJ (2008) Analysis of UDP-galactose 4¢-epimerase mutations associated with the intermediate form of type III galactosaemia J Inherit Metab Dis 31, 108–116
22 Timson DJ (2005) Functional analysis of disease-caus-ing mutations in human UDP-galactose 4-epimerase FEBS J 272, 6170–6177
23 Quimby BB, Alano A, Almashanu S, DeSandro AM, Cowan TM & Fridovich-Keil JL (1997) Characteriza-tion of two mutaCharacteriza-tions associated with epimerase-defi-ciency galactosemia, by use of a yeast expression system for human UDP-galactose-4-epimerase Am J Hum Genet 61, 590–598
24 Wasilenko J, Lucas ME, Thoden JB, Holden HM & Fridovich-Keil JL (2005) Functional characterization of the K257R and G319E–hGALE alleles found in patients with ostensibly peripheral epimerase deficiency galactosemia Mol Genet Metab 84, 32–38
25 Kingsley DM, Kozarsky KF, Hobbie L & Krieger M (1986) Reversible defects in O-linked glycosylation and
Trang 10LDL receptor expression in a UDP-Gal⁄ UDP-GalNAc
4-epimerase deficient mutant Cell 44, 749–759
26 Garcia-Mata R, Gao YS & Sztul E (2002) Hassles with
taking out the garbage: aggravating aggresomes Traffic
3, 388–396
27 Johnston JA, Ward CL & Kopito RR (1998)
Aggre-somes: a cellular response to misfolded proteins J Cell
Biol 143, 1883–1898
28 Schulz JM, Ross KL, Malmstrom K, Krieger M &
Fridovich-Keil JL (2005) Mediators of galactose
sensi-tivity in UDP-galactose 4¢-epimerase-impaired
mamma-lian cells J Biol Chem 280, 13493–13502
29 Wasilenko J & Fridovich-Keil JL (2006) Relationship
between UDP-galactose 4¢-epimerase activity and
galac-tose sensitivity in yeast J Biol Chem 281, 8443–8449
30 Shyu AB, Wilkinson MF & van Hoof A (2008)
Messen-ger RNA regulation: to translate or to degrade EMBO
J 27, 471–481
31 Kopito RR (2000) Aggresomes, inclusion bodies and
protein aggregation Trends Cell Biol 10, 524–530
32 Ramm M, Wolfender JL, Queiroz EF, Hostettmann K
& Hamburger M (2004) Rapid analysis of
nucleotide-activated sugars by high-performance liquid chromatog-raphy coupled with diode-array detection, electrospray ionization mass spectrometry and nuclear magnetic resonance J Chromatogr A 1034, 139–148
Supporting information
The following supplementary material is available: Fig S1 Summary of the functional consequences of human GALE mutations
Fig S2 Allelic interaction between the mutant alleles identified in Korean galactosemia patients
This supplementary material can be found in the online version of this article
Please note: Wiley-Blackwell is not responsible for the content or functionality of any supplementary materials supplied by the authors Any queries (other than missing material) should be directed to the corresponding author for the article